Ezaldein HH - Search Results

1

Three-dimensional orbital dysmorphology in metopic synostosis.

Ezaldein HH, Metzler P, Persing JA, Steinbacher DM. Ezaldein HH, et al. J Plast Reconstr Aesthet Surg. 2014 Jul;67(7):900-5. doi: 10.1016/j.bjps.2014.03.009. Epub 2014 Apr 13. J Plast Reconstr Aesthet Surg. 2014. PMID: 24820454

2

Comparing two fronto-orbital advancement strategies to treat trigonocephaly in metopic synostosis.

Metzler P, Ezaldein HH, Persing JA, Steinbacher DM. Metzler P, et al. Among authors: ezaldein hh. J Craniomaxillofac Surg. 2014 Oct;42(7):1437-41. doi: 10.1016/j.jcms.2014.04.006. Epub 2014 Apr 26. J Craniomaxillofac Surg. 2014. PMID: 24997751

3

Correction of severe enophthalmos by simultaneous fat grafting and anatomic orbital reconstruction.

Metzler P, Ezaldein HH, Pfaff MJ, Parsaei Y, Steinbacher DM. Metzler P, et al. Among authors: ezaldein hh. J Craniofac Surg. 2014 Sep;25(5):1829-32. doi: 10.1097/SCS.0000000000001057. J Craniofac Surg. 2014. PMID: 25203579

4

Grading of atypia in genital skin lesions: routine microscopic evaluation and use of p16 immunostaining.

Ezaldein H, Lott JP, McNiff JM, Hui P, Buza N, Ko CJ. Ezaldein H, et al. J Cutan Pathol. 2015 Aug;42(8):519-26. doi: 10.1111/cup.12525. Epub 2015 Jun 8. J Cutan Pathol. 2015. PMID: 25951050

5

The effect of comorbidities on overall mortality in Stevens- Johnson Syndrome: an analysis of the Nationwide Inpatient Sample.

Ezaldein H, Totonchy M, Chow C, Samuel A, Ventura A. Ezaldein H, et al. Dermatol Online J. 2017 Apr 15;23(4):13030/qt9333c5dw. Dermatol Online J. 2017. PMID: 28541871 Free article.

6

Risk stratification for cellulitis versus noncellulitic conditions of the lower extremity: a retrospective review of the NEW HAvUN criteria.

Ezaldein HH, Waldman A, Grunseich K, Jubanyik K. Ezaldein HH, et al. Cutis. 2018 Jul;102(1):E8-E12. Cutis. 2018. PMID: 30138510

7

Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.

Totonchy MB, Ezaldein HH, Ko CJ, Choi JN. Totonchy MB, et al. Among authors: ezaldein hh. JAMA Dermatol. 2016 May 1;152(5):590-2. doi: 10.1001/jamadermatol.2015.5210. JAMA Dermatol. 2016. PMID: 26675815 No abstract available.

8

Transparency and Dermatologic Device Approval by the US Food and Drug Administration.

Ezaldein HH, Scott JF, Yin ES, Ventura A, DeRuyter NP, Leffell DJ. Ezaldein HH, et al. JAMA Dermatol. 2018 Mar 1;154(3):273-280. doi: 10.1001/jamadermatol.2017.5757. JAMA Dermatol. 2018. PMID: 29365020 Free PMC article.

9

Induced clustered nanoconfinement of superparamagnetic iron oxide in biodegradable nanoparticles enhances transverse relaxivity for targeted theranostics.

Ragheb RR, Kim D, Bandyopadhyay A, Chahboune H, Bulutoglu B, Ezaldein H, Criscione JM, Fahmy TM. Ragheb RR, et al. Magn Reson Med. 2013 Dec;70(6):1748-60. doi: 10.1002/mrm.24622. Epub 2013 Feb 7. Magn Reson Med. 2013. PMID: 23401099 Free PMC article.

10

Understanding the influence of patient demographics on disease severity, treatment strategy, and survival outcomes in merkel cell carcinoma: a surveillance, epidemiology, and end-results study.

Ezaldein HH, Ventura A, DeRuyter NP, Yin ES, Giunta A. Ezaldein HH, et al. Oncoscience. 2017 Sep 14;4(7-8):106-114. doi: 10.18632/oncoscience.358. eCollection 2017 Jul. Oncoscience. 2017. PMID: 28966943 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters